Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged up 5% year-over-year to $12.5 billion but failed to match the expectations. Net loss for the quarter was $2.09 billion or $0.83 per share compared to a profit of $2.35 billion or $0.92 per share […]
Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged up 5% year-over-year to $12.5 billion but failed to match the expectations. Net loss for the quarter was $2.09 billion or $0.83 per share compared to a profit of $2.35 billion or $0.92 per share […]
Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020.
Worldwide sales edged up 5% year-over-year to $12.5 billion but failed to match the expectations.
Net loss for the quarter was $2.09 billion or $0.83 per share compared to a profit of $2.35 billion or $0.92 per share last year.
The adjusted EPS increased by 17% to $1.32 per share.
